LSC Abstract – Pleural inflammation is essential in bleomycin-induced lung toxicity

Archive ouverte

Burgy, Olivier | Bellaye, Pierre-Simon, Bellaye | Causse, Sebastien | Wettstein, Guillaume | Beltramo, Guillaume | Camus, Philippe | Garrido, Carmen | Goirand, Françoise | Bonniaud, Philippe

Edité par CCSD -

IF 10.569 . International audience. Introduction: In patients, the therapeutic use of bleomycin (BLM), a potent anticancerous drug, is strongly restrained because of its lung toxicity with pulmonary fibrosis (PF) being the most devastating form. Toxic and Idiopathic PF start classically in the subpleural area. It is know that 1) Pleural mesothelial cells (PMCs) acquire a TGF-β1-induced myofibroblast phenotype and 2) inflammation plays a significant role in fibrogenesis. The role of mesothelial cells in PF and in BLM lung toxicity has still to be investigated.Methods: C57Bl/6 mice were intravenously (IV) injected with BLM or NaCl. In vitro, human pleural mesothelial cells (Met5A) were treated with BLM.Results: Repeated IV BLM induces a peculiar lung fibrotic response with 1) an histological peripheral distribution, 2) a collagen accumulation in pleural and subpleural area, 3) an overexpression in PMCs of MMP-2, -9, HSP27, all involved in myofibroblast tranformation and 4) a migration of PMCs into the lung. This process was associated with an inflammatory profile with an increase 1) in neutrophils in pleural lavage fluid (PLF) and 2) an enhanced caspase-1 activity (total lung tissue). TGF-β1 was overexpressed in PLF. TGF-β1 and collagen accumulations were hampered after pleural inhibition of IL-1β (Anakinra intrapleural injection). IV administration of BLM triggered cell death in pleural and subpleural area (TUNEL). In vitro, BLM-induced cell death correlated with an increase in caspase-1 activity.Conclusion: IV BLM in rodent induces subpleural PF as observed in toxic and idiopathic PF in human. Our results demonstrate a key role of PMCs and suggest a caspase-1 dependent inflammation in this fibrogenesis process.

Consulter en ligne

Suggestions

Du même auteur

P087 Inhibition of pleural inflammation hampers with bleomycin-induced lung profibrotic toxicity.

Archive ouverte | Burgy, Olivier | CCSD

IF 2.824. International audience. The clinical use of bleomycin is restrained because of its lung toxicity with pulmonary fibrosis being the most devastating form. Toxic and idiopathic pulmonary fibrosis (PF) start ...

P105 Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity

Archive ouverte | Burgy, Olivier | CCSD

IF 2.824. International audience. Bleomycin is an anti-cancer drug used to treat different malignancies, mainly lymphomas, germ cell tumors. Unfortunately, bleomycin has major, pulmonary toxicity that affects 20% of...

Pleural inhibition of the caspase-1/IL-1β pathway diminishes profibrotic lung toxicity of bleomycin

Archive ouverte | Burgy, Olivier | CCSD

IF 3.751. International audience. Background: Idiopathic and toxic pulmonary fibrosis are severe diseases starting classically in the subpleural area of the lung. It has recently been suggested that pleural mesothel...

Chargement des enrichissements...